1. Search Result
Search Result
Pathways Recommended: TGF-beta/Smad
Results for "

Beta catenin

" in MedChemExpress (MCE) Product Catalog:

155

Inhibitors & Agonists

3

Screening Libraries

11

Peptides

19

Natural
Products

2

Recombinant Proteins

2

Isotope-Labeled Compounds

5

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-147007

    β-catenin Wnt Cancer
    β-catenin-IN-3 (compound C2) is a potent and selective β-catenin inhibitor with a KD value of 54.96 nM. β-catenin-IN-3 acts by targeting a cryptic allosteric modulation site of β-catenin. β-catenin-IN-3 can significantly reduce viability of β-catenin-driven cancer cells .
    <em>β</em>-<em>catenin</em>-IN-3
  • HY-10834

    β-catenin Cancer
    β-catenin-IN-6 is a β-catenin inhibitor, targeting to canonical Wingless-related integration site signaling pathway. β-catenin-IN-6 inhibits human colorectal cancer cells proliferation, as well as in a β-catenin/RK3E mouse model .
    <em>β</em>-<em>catenin</em>-IN-6
  • HY-147651

    β-catenin Cancer
    β-catenin-IN-4 (Compound 39) is a β-catenin inhibitor with a Ki of 0.64 μM. β-catenin-IN-4 reduces the protein expression levels of cyclin D1 and c-Myc .
    <em>β</em>-<em>catenin</em>-IN-4
  • HY-149858

    Wnt Cancer
    β-catenin-IN-7 (Compound 9) is a β-catenin inhibitor. β-catenin-IN-7 inhibits the interaction between β-catenin and Tcf-4, and inhibits Wnt-dependent target gene expression. β-catenin-IN-7 has anti-cancer activity .
    <em>β</em>-<em>catenin</em>-IN-7
  • HY-115543

    β-catenin Cancer
    β-catenin-IN-37 is a selective β-Catenin/T-cell factor protein-protein interaction (β-catenin/Tcf PPI) inhibitor. β-catenin-IN-37 inhibits canonical Wnt signaling and the growth of colorectal cancer cells SW480 and HCT116 with the IC50 values of 20 μM and 31 μM, respectively .
    <em>β</em>-<em>catenin</em>-IN-37
  • HY-136464
    β-catenin-IN-2
    1 Publications Verification

    β-catenin Cancer
    β-catenin-IN-2 is a potent β-catenin inhibitor, compound H1B1, extracted from patent US20150374662A1. β-catenin-IN-2 can be used for the study of colorectal cancer .
    <em>β</em>-<em>catenin</em>-IN-2
  • HY-153678

    β-catenin Cancer
    β-Catenin modulator-1 (IIa-650) is a β-Catenin modulator useful in cancer research .
    <em>β</em>-<em>Catenin</em> modulator-1
  • HY-157990

    Wnt β-catenin Cancer
    Wnt/β-catenin-in-1 (compounds 17) is a Wnt/β-catenin signaling pathway inhibitor. Wnt/β-catenin-IN-1 can induce apoptosis of colon cancer cells, has broad-spectrum anticancer activity, and can be used for the reseach of a variety of solid tumors .
    Wnt/<em>β</em>-<em>catenin</em>-IN-1
  • HY-153679

    β-catenin Cancer
    β-Catenin modulator-2 (compound IIa-130), an oxazole and thiazole compound, is a potent and selective β-Catenin modulator .
    <em>β</em>-<em>Catenin</em> modulator-2
  • HY-153680

    β-catenin Cancer
    β-Catenin modulator-3 (compound IIa-112), an oxazole and thiazole compound, is a potent and selective β-Catenin modulator .
    <em>β</em>-<em>Catenin</em> modulator-3
  • HY-153682

    β-catenin Cancer
    β-Catenin modulator-5 (compound IIa-84), an oxazole and thiazole compound, is a potent and selective β-Catenin modulator .
    <em>β</em>-<em>Catenin</em> modulator-5
  • HY-153681

    β-catenin Cancer
    β-Catenin modulator-4 (compound IIa-92), an oxazole and thiazole compound, is a potent and selective β-Catenin modulator .
    <em>β</em>-<em>Catenin</em> modulator-4
  • HY-148055

    β-catenin Cardiovascular Disease
    Wnt/β-catenin agonist 3 (compound 98) is a Wnt/β-catenin signalling pathway agonist. Wnt/β-catenin agonist 3 can be used for the research of osteoporosis .
    Wnt/<em>β</em>-<em>catenin</em> agonist 3
  • HY-148055A

    β-catenin Others
    Wnt/β-catenin agonist 3 hydrochloride is a Wnt/β-catenin signalling pathway agonist. Wnt/β-catenin agonist 3 (compound 98) can be used for the research of osteoporosis .
    Wnt/<em>β</em>-<em>catenin</em> agonist 3 hydrochloride
  • HY-160489

    β-catenin Cancer
    PTK7/β-catenin-IN-2 (compound 04967) is an inhibitor of PTK7/β-catenin. It inhibits the binding of PTK7 to β-catenin (IC50: 5.6 μM), thereby inhibiting the signaling of the Wnt/β-catenin pathway. PTK7/β-catenin-IN-2 targets cell growth dependent on the Wnt signaling pathway and has anticancer properties. PTK7/β-catenin-IN-2 also showed inhibitory potency against p53 and MDM2 binding with an IC50 of 157.1 μM .
    PTK7/<em>β</em>-<em>catenin</em>-IN-2
  • HY-155391

    Carbonic Anhydrase P-glycoprotein Wnt β-catenin Cancer
    hCA/Wnt/β-catenin-IN-1 (Compd 15) is an inhibitor of hCA (Ki: 33.6, 24.1, 6.8 nM for hCA II, hCA IX, hCA XII). hCA/Wnt/β-catenin-IN-1 reduces P-gp activity. hCA/Wnt/β-catenin-IN-1 also inhibits Wnt/β-catenin signaling pathway. hCA/Wnt/β-catenin-IN-1 inhibits cancer cell viability, including the NCI/ADR-RES DOX-resistant cell line .
    hCA/Wnt/<em>β</em>-<em>catenin</em>-IN-1
  • HY-160488

    β-catenin Cancer
    PTK7/β-catenin-IN-1 (compound 01065) is a potent PTK7/β-catenin inhibitor with an IC50 of 8.9 μM and 56.5 μM for PTK7/β-catenin and p53/MDM2, respectively. PTK7/β-catenin-IN-1 has the potential for cancer research .
    PTK7/<em>β</em>-<em>catenin</em>-IN-1
  • HY-151520

    Wnt Cancer
    Wnt/β-catenin agonist 4 (Derivative 83) is an agonist of Wnt that activates Wnt/β-catenin signal transmission .
    Wnt/<em>β</em>-<em>catenin</em> agonist 4
  • HY-141873

    β-catenin Others
    Wnt/β-catenin agonist 2 is a potent Wnt agonist. Wnt/β-catenin agonist 2 activates Wnt/β-catenin signaling and can be used in the research of diseases related to the signal transduction . (From patent WO2007078113A1, compound 39)
    Wnt/<em>β</em>-<em>catenin</em> agonist 2
  • HY-114321
    Wnt/β-catenin agonist 1
    4 Publications Verification

    Wnt Cancer
    Wnt/β-catenin agonist 1 (compound 3f) is a Wnt/β-catenin signalling pathway agonist, with an EC50 of 0.27 μM .
    Wnt/<em>β</em>-<em>catenin</em> agonist 1
  • HY-161087

    β-catenin Cancer
    β-catenin/BCL9 PPI-IN-1 (compound B4) is a potent inhibitor of β catenin/B-Cell lymphoma 9 protein?protein interaction (β catenin/BCL9 PPI) with the IC50 value of 2.25 μM .
    <em>β</em>-<em>catenin</em>/BCL9 PPI-IN-1
  • HY-160493

    Wnt β-catenin Cancer
    PTK7/β-catenin-IN-6 (Compound 03653) is an inhibitor for PTK7/β-catenin interaction, which inhibits the Wnt signaling pathway, and exhibits an anticancer activity against colorectal cancer (CRC) .
    PTK7/<em>β</em>-<em>catenin</em>-IN-6
  • HY-101085
    SKL2001
    35+ Cited Publications

    SKL2001 is an agonist of the Wnt/β-catenin pathway, with anti-cancer activity. SKL2001 stabilizes intracellular β-catenin via disruption of the Axin/β-catenin interaction .
    SKL2001
  • HY-115539

    Wnt β-catenin Histone Acetyltransferase Cancer
    Windorphen is a Wnt/β-catenin signal inhibitor that specifically targets the function of the c-terminal transactivation domain of β-catenin-1 but not β-catenin-2. Windorphen selectively targets p300, disrupting the association of the mammalian β-catenin with p300 but not CBP .
    Windorphen
  • HY-109103
    Tegatrabetan
    1 Publications Verification

    Tegavivint; BC2059

    β-catenin Cancer
    Tegatrabetan (BC2059) is a β-Catenin antagonist. Tegatrabetan disrupts the binding of β-catenin with the scaffold protein transducin β-like 1 (TBL1) .
    Tegatrabetan
  • HY-120697
    MSAB
    10+ Cited Publications

    Wnt β-catenin Cancer
    MSAB is a potent and selective inhibitor of Wnt/β-catenin signaling. MSAB binds to β-catenin promoting its degradation, and specifically downregulates Wnt/β-catenin target genes. MSAB exhibits potent anti-tumor effects selectively on Wnt-dependent cancer cells .
    MSAB
  • HY-119383

    β-catenin Cancer
    iCRT-5 is a β-catenin-regulated transcription (CRT) inhibitor. iCRT-5 can block Wnt/β-catenin reporter activity and down regulate β-catenin expression. iCRT-5 can be used for the research of multiple myeloma .
    iCRT-5
  • HY-122649

    β-catenin Cancer
    UU-T01 is a selective inhibitor for β-Catenin/T-cell factor 4 protein-protein interaction (β-catenin/Tcf PPI) with an Ki value of 3.14 µM. UU-T01 is directly combined with β-catenin, and the KD value is 0.531 µM .
    UU-T01
  • HY-132300

    β-catenin Cancer
    ZW4864 is an orally active and selective β catenin/B-Cell lymphoma 9 protein−protein interaction (β catenin/BCL9 PPI) inhibitor. ZW4864 inhibits β catenin/BCL9 PPI with a Ki value of 0.76 μM and an IC50 value of 0.87 μM .
    ZW4864
  • HY-102028
    KY1220
    3 Publications Verification

    Wnt β-catenin Cancer
    KY1220 is a compound that destabilizes both β-catenin and Ras, via targeting the Wnt/β-catenin pathway; with an IC50 of 2.1 μM in HEK293 reporter cells.
    KY1220
  • HY-P5819A

    PROTACs β-catenin Cancer
    xStAx-VHLL TFA, a PROTAC, sustains β-catenin degradation and manifested strong inhibition of Wnt signaling. xStAx-VHLL TFA promotes β-catenin ubiquitination .
    xStAx-VHLL TFA
  • HY-111760

    Molecular Glues β-catenin Cancer
    NRX-252262 is a potent enhancer of the interaction between β-Catenin, and its cognate E3 ligase, SCF β-TrCP, induces mutant β-catenin degradation, with an EC50 of 3.8 nM .
    NRX-252262
  • HY-14428
    ICG-001
    35+ Cited Publications

    β-catenin Apoptosis Cancer
    ICG-001 is an inhibitor of β-catenin/TCF mediated transcription. ICG-001 works by specifically binding to cyclic AMP response element-binding protein with an IC50 of 3 μM. ICG-001 selectively blocks the β-catenin/CBP interaction without interfering with the β-catenin/p300 interaction.
    ICG-001
  • HY-132300A

    β-catenin Cancer
    ZW4864 (free base) is an orally active and selective β catenin/B-Cell lymphoma 9 protein−protein interaction (β catenin/BCL9 PPI) inhibitor. ZW4864 (free base) inhibits β catenin/BCL9 PPI with a Ki value of 0.76 μM and an IC50 value of 0.87 μM .
    ZW4864 free base
  • HY-111836

    Molecular Glues β-catenin Cancer
    NRX-252114 is a potent enhancer of the interaction between β-catenin, and its cognate E3 ligase, SCF β-TrCP. NRX-252114 enhances the binding of pSer33/S37A β-catenin peptide for β-TrCP with an EC50 of 6.5 nM and a Kd of 0.4 nM. NRX-252114 induces mutant β-catenin degradation .
    NRX-252114
  • HY-P4858

    GSK-3 Cancer
    C-Peptide 1 (rat), a peptide, is aβ-catenin/GSK-3β activator. C-Peptide 1 (rat) can regulate the Wnt/β-catenin signaling pathway. C-Peptide 1 (rat) can be used for the research of cancer .
    C-Peptide 1 (rat)
  • HY-10593

    Wnt Others
    IQ 1 is a Wnt/β-catenin/CBP signalling sustainer. IQ 1 maintains long-term expansion of Wnt/β-catenin-driven mouse embryonic stem cells (ESCs) and prevents spontaneous differentiation by enhancing β-catenin/CBP-mediated transcription and preventing conversion to β-catenin/p300-mediated transcription. IQ-1 regulates Wnt signalling by interacting with PR72/130. IQ 1 can be used in study of ESCs expansion .
    IQ 1
  • HY-141448

    β-catenin Cancer
    NRX-2663 is an enhancer of the interaction between β-catenin, and its cognate E3 ligase, SCF β-TrCP. NRX-2663 enhances the binding of β-catenin peptide for β-TrCP with an EC50 of 22.9 µM and a Kd of 54.8 nM .
    NRX-2663
  • HY-144982

    Others Cancer
    NRX-1532 is a small molecule enhancer of β-catenin:β-TrCP interaction.
    NRX-1532
  • HY-10590
    TWS119
    20+ Cited Publications

    GSK-3 Autophagy Neurological Disease Cancer
    TWS119 is a specific inhibitor of GSK-3β, with an IC50 of 30 nM, and activates the wnt/β-catenin pathway.
    TWS119
  • HY-141450

    β-catenin Cancer
    NRX-103095 is an enhancer of the interaction between β-catenin, and its cognate E3 ligase, SCF β-TrCP. NRX-103095 enhances the binding of pSer33/Ser37 β-catenin peptide for β-TrCP with an EC50 of 163 nM .
    NRX-103095
  • HY-144984

    Others Cancer
    NRX-1933 is a β-catenin:β-TrCP interaction enhancer for the development of small molecule degraders.
    NRX-1933
  • HY-110074

    Others Others
    TWS119 TFA is a specific inhibitor of GSK-3β, with an IC50 of 30 nM, and activates the wnt/β-catenin pathway.
    TWS119 TFA
  • HY-111386

    Epigenetic Reader Domain Cancer
    E-7386 is an orally active CBP/beta-catenin modulator.
    E-7386
  • HY-112045
    Foscenvivint
    1 Publications Verification

    PRI-724

    Wnt Cancer
    PRI-724 is a selective inhibitor of the CBP/β-catenin interaction.
    Foscenvivint
  • HY-133180

    Wnt β-catenin Metabolic Disease
    YW1128 (compound 3a) is a potent Wnt/β-Catenin inhibitor. YW1128 induces the proteasome degradation of β-catenin and subsequent inhibits the Wnt/β-catenin signaling in cells. YW1128 significantly decreases hepatic lipid accumulation. YW1128 improves glucose tolerance of high fat diet-fed mice without noticeable toxicity. YW1128 down regulates the genes involved in the glucose and fatty acid anabolism .
    YW1128
  • HY-141449

    Molecular Glues β-catenin Cancer
    NRX-103094 is a potent enhancer of the interaction between β-catenin, and its cognate E3 ligase, SCF β-TrCP. NRX-103094 enhances the binding of pSer33/Ser37 β-catenin peptide for β-TrCP with an EC50 of 62 nM and a Kd of 0.6 nM .
    NRX-103094
  • HY-15721
    FH535
    10+ Cited Publications

    PPAR Wnt β-catenin Cancer
    FH535 is an inhibitor of Wnt/β-catenin and PPAR, with anti-tumor activities.
    FH535
  • HY-103705
    iCRT3
    5+ Cited Publications

    Wnt Apoptosis Cancer
    iCRT3 is an inhibitor of both Wnt and β-catenin-responsive transcription.
    iCRT3
  • HY-112799

    Wnt β-catenin Cancer
    DK419 is a potent and orally active Wnt/β-catenin signaling inhibitor, with an IC50 of 0.19 μM. DK419 reduces protein lelvels of Axin2, β-catenin, c-Myc, Cyclin D1 and Survivin and induces production of pAMPK .
    DK419

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: